Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILOT Software, a robotic platform for transcatheter aortic valve implantation; TAVIPILOT Robot, mitral valve repair and replacement solutions; MITRAPILOT, a biomimetic transcatheter mitral valve; and Artedrone, an implantable artificial urinary sphincter. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026. Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.
Frequently asked questions
What sector does Carvolix (CVX) operate in?
Carvolix belongs to the Other sector and operates in the Medical Devices industry.
What is Carvolix (CVX) current stock price?
As of the latest data, Carvolix stock price is €5.88, with a previous close of €5.88.
What is Carvolix (CVX) current market capitalization?
Carvolix market cap is approximately 365.93 million.
What is Carvolix (CVX) Earnings Per Share (EPS)?
The trailing EPS is -€0.65, and the forward EPS is -€0.45.
What is Carvolix (CVX) EBITDA?
Carvolix EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -13.30 million.
Does Carvolix (CVX) pay dividends?
No. Carvolix does not pay a dividend.
What is Carvolix (CVX) beta (volatility) score?
Carvolix has a beta of 1.164, meaning its volatility is roughly in line with the market.
